| Literature DB >> 35673812 |
Ioana Cristina Niculescu Talpoş1, Ramona Camelia Rumel, Alexandra Denisa Scurtu, Ştefania Dinu, Mariana Ioana Miron, Antoaneta Denisa Preduţ, Raluca Mioara Cosoroabă, Ramona Amina Popovici, Marius Raica.
Abstract
Malignant tumors of the oral cavity have a growing incidence, most being squamous cell carcinomas, generally called oral cancers (OCs), clinically detected at various stages of natural evolution. The increased incidence in Romania in recent years and the lack of conclusive data have led to the development of this study. The main purpose of this study was to assess the molecular profile of tumors, the types of blood vessels associated with the tumor, and expression of tumor immunomarkers. Regarding morphological findings, focal epithelial hyperplasia, dysplastic lesions, typical mitoses, perineural invasion, parakeratosis and keratosis beads, intracytoplasmic keratinization were observed. Microvascular density was higher in the tumor area compared to the peritumoral area. Lymphovascular invasion was identified in 13% of cases, which also presented regional lymph node metastases. Podoplanin expression was identified in 79% of cases which were tested positive for the D2-40 immunomarker. All p53-positive cases co-expressed epidermal growth factor receptor (EGFR), half of the EGFR-positive cases co-expressed p53, and co-expression of CD117 and p63 was identified in 80% of EGFR-positive∕cytokeratin 5 (CK5)-positive cases being proposed the basal-like subtype of OCs, defined as EGFR-positive∕CK5-positive, CD117-positive and p63-positive. Results support the need for molecular classification of OCs based on of tumor immunomarker expression and gene analysis.Entities:
Mesh:
Substances:
Year: 2021 PMID: 35673812 PMCID: PMC9289717 DOI: 10.47162/RJME.62.4.05
Source DB: PubMed Journal: Rom J Morphol Embryol ISSN: 1220-0522 Impact factor: 0.833
Antibodies, working system, and expression of the final product
|
|
|
|
|
|
|
|
|
Ki67 |
MIB1 |
RTU |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Nuclear |
|
p53 |
DO7 |
RTU |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Nuclear |
|
Bcl-2 |
124 |
RTU |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Nuclear, cytoplasmic |
|
E-cadherin |
NCH 38 |
1:100 |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Membrane/ cytoplasmic or both |
|
CK 5/6 |
D5/16 B4 |
1:80 |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Cytoplasmic |
|
EGFR |
Polyclonal |
RTU |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
EGFR pharmDx™ visualization reagent, DAB |
Membrane, cytoplasmic |
|
CD117 |
c-kit |
1:300 |
MW, 30 minutes citrate buffer, pH 6 |
30 minutes, RT |
LSAB+/HRP, DAB |
Cytoplasmic, granular |
Bcl-2: B-cell lymphoma-2; CD117: Cluster of differentiation 117; CK 5/6: Cytokeratin 5/6; DAB: 3,3’-Diaminobenzidine; EGFR: Epidermal growth factor receptor; HRP: Horseradish peroxidase; LSAB: Labeled Streptavidin–Biotin; MW: Microwave; RT: Room temperature; RTU: Ready-to-use.
Figure 1The rate of occurrence of the usual morphological changes detected in the case of premalignant and malignant oral diseases in 92 analyzed samples
Figure 2D2-40-positive immunoreaction for lymphatic vessels: (a and b) Lymphatic vessels – peritumoral area; (c) Lymphatic vessels – interface between tumor cells and stroma; (d) Group of tumor cells surrounded by endothelial cells
Figure 3Immunoreaction for EGFR: (a) Membrane-restricted reaction final product and (b) cytoplasmic final reaction product. (c) Immunoreaction to CK5, over 20% of tumor cells are positive at the membrane level. (d) Overview of the reaction for CD117 in HNSCCs, (e) CD117-positive cell agglomerations at the front of squamous proliferation, (f) presence of non-tumor positive CD117 cells among the malignant elements. (g) Reaction for p53 nuclear-restricted. CD117: Cluster of differentiation 117; CK5: Cytokeratin 5; EGFR: Epidermal growth factor receptor; HNSCCs: Head and neck squamous cell carcinomas
Heterogeneity of expression of investigated markers
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
|
- |
- |
- |
+ |
+ |
|
- |
+ |
+ |
+ |
+ |
|
+ |
+ |
+ |
+ |
+ |
Bcl-2: B-cell lymphoma-2; EGFR: Epidermal growth factor receptor